AFP and hepatocellular carcinoma: Here, we designed a large‐scale multistage study to identify the potential TAAbs, and developed an immunodiagnostic model for HCC detection, which could discriminate AFP‐negative HCC patients from normal control (NC), and also early‐stage HCC patients from NC, CHB control, the at‐risk control, LC control, and all non‐HCC control.